We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Elevated plasma big ET‐1 is associated with distant failure in patients with advanced‐stage nasopharyngeal carcinomaThe present study was carried out with ethical committee approval. Informed consent was obtained from all patients and control participants.
- Authors
Hai‐Qiang Mai; Zong‐Yuan Zeng; Chang‐Qing Zhang; Kai‐Tao Feng; Xiang Guo; Hao‐Yuan Mo; Man‐Quan Deng; Hua‐Qing Min; Ming‐Huang Hong
- Abstract
Endothelin‐1 (ET‐1) is a potent vasoactive peptide and a hypoxia‐inducible angiogenic growth factor associated with the development and spread of solid tumors. The clinical significance of plasma big ET‐1 in patients with advanced‐stage nasopharyngeal carcinoma (NPC) is not known.Pretreatment plasma big ET‐1 levels were measured in 62 patients with advanced‐stage NPC using a sandwich enzyme‐linked immunoassay and compared with the levels from a control group (n = 19 participants).The median pretreatment plasma big ET‐1 level in patients with advanced‐stage NPC was 4.6 pg/mL (range, 1.9‐15.2 pg/mL) and was significantly elevated compared with median plasma big ET‐1 levels in healthy controls, 2.6 pg/mL (1.6‐4.5 pg/mL) (P < .001). Using the upper limit (4.5 pg/mL) of control subjects as the cut‐off value, plasma big ET‐1 was ≤ 4.5 pg/mL in 29 (46.8%) patients and > 4.5 pg/mL in 33 (53.2%) patients. A pretreatment plasma big ET‐1 level > 4.5 pg/mL was associated with a significantly poorer 2‐year distant metastasis‐free survival rate (56.7% vs. 81.1%, P = .031). Multivariate analysis showed that N classification (hazard ratio [HR], 2.416; 95% confidence interval [CI], 1.071‐5.447; P = .034) and pretreatment plasma big ET‐1 level (HR, 3.151; 95% CI, 1.099‐9.028, P = .033) were independent significant prognostic factors for posttreatment distant failure in patients with advanced‐stage NPC.Pretreatment plasma big ET‐1 levels may be useful in predicting posttreatment distant failure in patients with advanced‐stage NPC. Cancer 2006. © 2006 American Cancer Society.
- Subjects
ENDOTHELINS; VASOACTIVE intestinal peptide; HYPOXEMIA; GROWTH factors; TUMORS; CANCER invasiveness
- Publication
Cancer (0008543X), 2006, Vol 106, Issue 7, p1548
- ISSN
0008-543X
- Publication type
Article